Iron chelation therapy associated with improvement of hematopoiesis in transfusion‐dependent patients
- 1 July 2010
- journal article
- case report
- Published by Wiley in Transfusion
- Vol. 50 (7) , 1568-1570
Abstract
BACKGROUND: It is well known that iron overload may cause multiple organ failure. In chronically transfused patients, optimal iron chelation therapy is associated with reduced morbidity and mortality. Furthermore, chelation therapy has been associated with erythroid responses.STUDY DESIGN AND METHODS: Among chronically transfused adults affected by myeloproliferative neoplasms and treated with iron chelators, two case reports are described.CASE REPORT: A male adult patient with myelodysplastic syndrome (MDS) and a female adult with aplastic anemia (AA), both transfusion‐dependent, were treated with deferasirox, an oral iron chelator.RESULTS: A significant reduction in transfusion requirement was observed and was dependent on chelation therapy. The patient affected by AA also experienced a significant increase in hemoglobin levels. Minimal doses of deferasirox maintained the erythroid responses. Many mechanisms of action of the drug on erythropoiesis have been postulated. The early erythroid response seems to be independent of the removal of iron from deposits, per se, since the reduction of ferritin levels (a surrogate marker of iron deposits) below threshold levels occurs as a later event.CONCLUSION: Although there are few reports on erythroid responses in patients undergoing iron chelation therapy, they may give new insights in the pathogenesis of MDS and other myeloproliferative neoplasms. AA may benefit in terms of erythroid response. The findings in these cases underline the clinical importance of treating patients with iron overload. A survival benefit of chelation in patients with myeloproliferative neoplasms is still to be confirmed.Keywords
This publication has 10 references indexed in Scilit:
- Deferasirox Treatment Improved the Hemoglobin Level and Decreased Transfusion Requirements in Four Patients with the Myelodysplastic Syndrome and Primary MyelofibrosisActa Haematologica, 2008
- Correction of anemia in a transfusion‐dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade®, ICL670)European Journal of Haematology, 2007
- Polycythemia vera: myths, mechanisms, and managementBlood, 2002
- The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overloadBritish Journal of Haematology, 1996
- Improvement of erythropoiesis during treatment with deferiprone in a patient with myelofibrosis and transfusional hemosiderosisAmerican Journal of Hematology, 1996
- Iron Chelators May Enhance Erythropoiesis by Increasing Iron Delivery to Haematopoietic Tissue and Erythropoietin Response in Iron-Loading AnaemiaActa Haematologica, 1993
- Uptake and intracellular distribution of iron from transferrin and chelators in erythroid cellsBioMetals, 1990
- Regulation of transferrin receptors in human hematopoietic cell lines.Journal of Biological Chemistry, 1984
- IMPROVEMENT IN IRON STATUS AND LIVER FUNCTION IN PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD WITH LONG-TERM SUBCUTANEOUS DESFERRIOXAMINEThe Lancet, 1979
- Long-term administration of desferrioxamine in thalassaemia majorArchives of Disease in Childhood, 1974